Name: LIU Ying

Subject: Tumor Biology

Tel/Fax: +86-532-82991791

Email:    liuying_hero@163.com; yingliu@qdu.edu.cn

Address: Ningde Road 1#, Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao Medical College, Qingdao University, Qingdao 266073, China

Resume:

LIU Ying, Ph.D., graduated from School of Life Science and Technology, Dalian University of Technology in 2015. In the same year, he joined the Institute for Translational Medicine, Qingdao University. In 2020, he was selected into the project “Youth Outstanding Talents of Qingdao University”. Dr. Liu is Handling Editor of “Frontiers in Oncology”, Guest Editor/Editorial Board Member of “Oncology Letters”, Council Member of Shandong Medical Ethics Society, Regular Member of Chinese Society for Biochemistry and Molecular Biology, and Regular Member of Chinese Society for Cell Biology. Dr. Liu research interests cover basic and applied research on nuclear receptor signal transduction, protein post-translational modification, identification of tumor biomarkers, and bioinformatics. In recent years, he has published more than 50 SCI articles in biomedical-related fields, including 27 papers published by the first author or corresponding author. Dr. Liu has been awarded many prizes and honors, including the First Prize for Liaoning Natural Science Academic Achievement Award, the Third Prize for Liaoning Natural Science Academic Achievement Award, the First Prize for Dalian Science and Technology Award, the First Prize for Excellent academic paper award of Dalian Academy of Natural Sciences, the Second Prize for Dalian Science and Technology Award, Award for Graduate Student Fellowship Award of Dalian University of Technology.

Selected Publications:

1. Ying Liu^#,*, Xiang Ao, Wanpeng Yu, Yuan Zhang, and Jianxun Wang (2022). Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer. Molecular Therapy Nucleic Acid, 27:50-72. (IF: 10.183)

2. Ying Liu^#,*, Yu Wang, Xiaoge Li, Yi Jia, Jianxun Wang, and Xiang Ao (2022). FOXO3a in cancer drug resistance. Cancer Letters, 540:215724. (IF: 9.756)

3. Ying Liu^#,*, Xiaoge Li, Xuehao Zhou, Jianxun Wang, and Xiang Ao (2022). FADD as a key molecular player in cancer progression. Molecular Medicine, 28(1):132. (IF: 6.375)

4. Xiang Ao^# and Ying Liu^* (2022). Novel insights into circular RNA regulation in arsenic-exposureinduced lung cancer. Molecular Therapy Oncolytics. 27:200-202. (IF: 6.311)

5. Wei Ding^#, Ying Liu^#, Zhe Su, Qi Li, Jianxun Wang^*, and Yufang Gao^* (2022). Emerging role of non-coding RNAs in aortic dissection. Biomolecules, 12:1336. (IF: 6.064)

6. Ying Liu^#,*, Xiang Ao, Yu Wang, Xiaoge Li, and Jianxun Wang (2022). Long non-coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance. Frontiers in Oncology, 12:841411. (IF: 5.738)

7. Xuehao Zhou, Xiang Ao, Zhaojun Jia, Yiwen Li, Shouxiang Kuang, Chengcheng Du, Jinyu Zhang, and Ying Liu^* (2022). Non-Coding RNA in Cancer Drug Resistance: Underlying Mechanisms and Clinical Applications. Frontiers in Oncology, 12:951864. (IF: 5.738)

8. Ying Liu^#,*, Yiwen Li, Chengcheng Du, Shouxiang Kuang, Xuehao Zhou, Jinyu Zhang, and Xiang Ao (2022). Underlying mechanisms of epithelial splicing regulatory proteins in cancer progression. Journal of Molecular Medicine, 100(11):1539-1556. (IF: 5.606) (Cover illustration)

9. Ying Liu^#,*, Xiang Ao, Yi Jia, Xiaoge Li, Yu Wang, and Jianxun Wang (2022). The FOXO family of transcription factors: key molecular playersin gastric cancer. Journal of Molecular Medicine, 100(7):997-1015. (IF: 5.606) (Cover illustration)

10. Ying Liu^#,*, Xiang Ao, Xuehao Zhou, Chengcheng Du, and Shouxiang Kuang (2022). The regulation of PBXs and their emerging role in cancer. Journal of Cellular and Molecular Medicine, 26(5):1363–1379. (IF: 5.295)

11. Ying Liu^#, Wei Ding, Wanpeng Yu, Yuan Zhang, Xiang Ao^*, and Jianxun Wang^* (2021). Long non-coding RNAs: Biogenesis, functions, and clinical significance in gastric cancer. Molecular Therapy Oncolytics. 23:458-476. (IF: 6.311)

12. Ying Liu^#,*, Xiang Ao, Guoqiang Ji, Yuan Zhang, Wanpeng Yu, and Jianxun Wang (2021). Mechanisms of action and clinical implications of microRNAs in the drug resistance of gastric cancer. Frontiers in Oncology. 11:768918. (IF: 5.738)

13. Wenwen Marin^#,*, Dennis Marin, Xiang Ao, and Ying Liu^* (2021). Mitochondria as a therapeutic target for cardiac ischemia reperfusion injury (Review). International Journal of Molecular Medicine. 47(2):485-499. (IF: 5.314)

14. Xinyu Liu^#, Ying Liu^#, Qianshan Wang, Siqi Song, Lingjun Feng^*, and Chunying Shi^* (2021). The alterations and potential roles of MCMs in breast cancer. Journal of Oncology. 2021:7928937. (IF: 4.501)

15. Xinyu Liu^#, Qianshan Wang, Siqi Song, Manman Feng, Xiaoya Wang, Ling Li, Ying Liu^*, and Chunying Shi^* (2021). Epithelial splicing regulatory protein 1 is overexpressed in breast cancer and predicts poor prognosis for breast cancer patients. Medical Science Monitor. 27:e931102. (IF: 3.386)

16. Xiang Ao^#, Wei Ding, Yuan Zhang, Dan Ding, and Ying Liu^* (2020).TCF21: a critical transcription factor in health and cancer. Journal of Molecular Medicine, 98(8):1055-1068. (IF: 5.606)

17. Xiang Ao^#, Wei Ding, Hu Ge, Yuan Zhang, Dan Ding, and Ying Liu^* (2020). PBX1 is a valuable prognostic biomarker for patients with breast cancer. Experimental and Therapeutic Medicine, 20(1):385-394. (IF: 2.751)

18. Haotian Lu^#, Chunying Shi^#, Xinyu Liu, Chen Liang, Chaochao Yang, Xueqi Wan, Ling Li^*, and Ying Liu^* (2020). Identification of ZG16B as a prognostic biomarker in breast cancer. Open Medicine, 16(1):1-13. (IF: 2.123)

19. Baowei Li^#, Xiong Wang^#, Xiaodan Hao, Yanran Liu, Yin Wang, Chan Shan, Xiang Ao, Ying Liu^*, Hongchu Bao^*, and Peifeng Li^* (2020). A novel c.2179T>C mutation blocked the intracellular transport of PHEX protein and caused X-linked hypophosphatemic rickets in a Chinese family. Molecular Genetics & Genomic Medicine, 8(8):e1262. (IF: 2.473)

20. Ying Liu^#, Wei Ding, Hu Ge, Murugavel Ponnusamy, Qiong Wang, Xiaodan Hao, Wei Wu, Yuan Zhang, Wanpeng Yu, Xiang Ao^*, and Jianxun Wang^* (2019). FOXK Transcription Factors: Regulation and Critical Role in Cancer. Cancer Letters, 458:1-12. (IF: 9.756)

21. Ying Liu^#,* (2019). Targeting the Non-Canonical AKT-FOXO3a Axis: A Potential Therapeutic Strategy for Oral Squamous Cell Carcinoma. EBioMedicine, 49:6-8. (IF: 11.205)

22. Ying Liu^#, Xiang Ao^#, Wei Ding, Murugavel Ponnusamy, Wei Wu, Xiaodan Hao, Wanpeng Yu, Yifei Wang, Peifeng Li^*, and Jianxun Wang^* (2018). Critical role of FOXO3a in carcinogenesis. Molecular Cancer, 17(1):104. (IF: 41.444)

23. Ying Liu^#, Xiang Ao, Qiong Wang, Jianxun Wang, Hu Ge* (2018). PiViewer: An open‐source tool for automated detection and display of π–π interactions. Chemical Biology & Drug Design, 92(4), 1809-1814. (IF: 2.873)

24. Chao Qu^#, Jia Sun^#, Ying Liu^#, Xiaobo Wang, Lifen Wang, Chao Han, Qian Chen, Tianhui Guan, Hongyan Li, Yejun Zhang, Yang Wang, Jia Liu, Wei Zou^*, and Jing Liu* (2018). Caveolin-1 Facilitated KCNA5 Expression, Promoting Breast Cancer Viability. Oncology Letters,16(4):4829-4838. (IF: 3.111)

25. Ying Liu^#, Xiang Ao^#, Zhaojun Jia, Xiaoyan Bai, Zhaowei Xu, Gaolei Hu, Xiao Jiang, Min Chen, and Huijian Wu^* (2015). FOXK2 Transcription Factor Suppresses ERα-positive Breast Cancer Cell Growth Through Down-Regulating the Stability of ERα via mechanism involving BRCA1/BARD1. Scientific Reports, 5:8796. (IF: 4.996)

26. Xiang Ao^#, Ying Liu^#, Xiaoyan Bai, Xinjian Qu, Zhaowei Xu, Gaolei Hu, Min Chen, and Huijian Wu^* (2015). Association between EHBP1 rs721048(A＞G) polymorphism and Prostate Cancer Susceptibility: A Meta-Analysis of 17 Studies Involving 150,678 Subjects. OncoTargets and Therapy, 8:1671-80. (IF: 4.345)

27. Ying Liu^#, Dongdong Chen, Yongheng Xing, Nan Ge, Yuan Zhang, Jing Liu, Wei Zou^* (2014). A new oxovanadium complex enhances renal function by improving insulin signaling pathway in diabetic mice. Journal of Diabetes and Its Complications, 28(3):265-72. (IF: 3.219)